Hemodiafiltration (HDF) for the treatment of end-stage renal disease patients is predominately performed in European countries and in Japan, with some differences in technique such as rate of blood flow and dialysis fluid delivery systems.

The main focus of this book is on the clinical importance of online HDF, the techniques of which have been re-evaluated with the introduction of super high-flux membrane dialyzers. After a brief introduction into the history of HDF, recent advances and clinical experiences of HDF are summarized, including water quality control for dialysis fluid, equipped system for safe use, clinical advantages, and theoretical aspects of HDF. Moreover, at the end of each chapter researchers and scientists discuss problems into which further research is needed.

Clinicians and scientists involved in the treatment of end-stage renal diseases patients will find this publication an essential source of information and quality control for dialysis fluid, equipped system for safe use, clinical advantages, and theoretical aspects of HDF. Moreover, at the end of each chapter researchers and scientists discuss problems into which further research is needed.

Hemodiafiltration – A New Era

Editors
Hideki Kawanishi
Akihiro C. Yamashita

Contents
Preface: Kawanishi, H.; Yamashita, A.C.
History and Evolution of Hemodiafiltration
Dawn of Hemodiafiltration: Ota, K.
Hemodiafiltration – State of the Art: Locatelli, F. et al.
Hemodiafiltration: Evolution of a Technique Towards Better Dialysis Care: Ronco, C.
Clinical Benefits of Hemodiafiltration
Optimal Therapeutic Conditions for Online Hemodiafiltration: Canaud, B. et al.
How to Prescribe Hemodialysis or Hemodiafiltration in Order to Ameliorate Dialysis-Related Symptoms and Complications: Masakane, I.
Optimizing Home Dialysis: Role of Hemodiafiltration: Vifì er, E. et al.
Management of Dialysis Fluid and Dialysis System
Quality Management of Dialysis Fluid for Online Convective Therapies: Ward, R.A.
Biocompatibility of Dialysis Fluid for Online HDF: Toma, T.; Shinoda, T.
Fully Automated Dialysis System for Online Hemodiafiltration Built into the Central Dialysis Fluid Delivery System: Kawanishi, H.; Morishii, M.

Uremic Toxins
New Uremic Toxins – Which Solutes Should Be Removed? Glorieux, G.; Vonhalden, R.
Beta-2-Microglobulin as a Uremic Toxic: the Japanese Experience: Fujimori, A.
Markers and Possible Uremic Toxins: Japanese Experiences: Kinugasa, E.

Dialysis Membranes for Hemodiafiltration
Biocompatibility of the Dialysis Membrane: Takemoto, Y. et al.
Choice of Dialyzers for HDF: Yamashita, A.C.; Sakurai, K.
Estimation of Internal Filtration Flow Rate in High-Flux Dialyzers by Doppler Ultrasonography: Mineshima, M.

Clinical Aspects of Hemodiafiltration
Management of Anemia by Convective Treatments: Locatelli, F. et al.
Clinical Evaluation Indices for Hemodialysis/Hemodiafiltration in Japan: Shinoda, T.; Koda, Y.
Effect of Large-Size Dialysis Membrane and Hemofiltration/Hemodiafiltration Methods on Long-Term Dialysis Patients: Tsuchida, K.; Minakuchi, J.
Who Needs Acetate-Free Biofiltration? Kano, T.
Preservation of Residual Renal Function with HDF: Fujisawa

www.karger.com/conep

Please send: ___ copies
Payment: Please charge to my credit card
☐ American Express  ☐ Diners  ☐ Eurocard
☐ MasterCard  ☐ Visa
Card No: ____________________________
Exp. date: ____________________________
CVV/CVC: ___________________________
(3 digits in the signature field on the back of Visa and MasterCard)
☐ Check enclosed  ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Fax: +41 61 306 12 34
S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
E-Mail orders@karger.ch, www.karger.com

Name/Address: ____________________________________________________________
________________________________________________________
________________________________________________________
Date:
Signature: _____________________________________________
Guidelines for Authors

Submission
Manuscripts for Nephron Experimental Nephrology should be submitted online at
www.karger.com/nef

Should you experience problems with your submission, please contact the Administrative Editor, Susan Beesley
E-Mail nephron@ucl.ac.uk
Tel. ++44 20 7679 0866
Fax ++44 20 7679 0887

All manuscripts undergo a preliminary review by the Editors. If it is found that an article would be more suit-
able for a sub-journal other than that selected by the au-
tors, the Editorial Office will re-assign the article ap-
propriately. Corresponding Authors will be informed of
any reassignment.

Minireviews: Are to be submitted only by invitation from
the Editor, although prospective authors are welcome to
contact the Editor to discuss whether a topic might be
suitable for a Minireview via nephron@ucl.ac.uk.

Suggested reviewers: Please list four complete mailing
e-mail addresses of potential reviewers for your manu-
script. The names you suggest should not be ‘Nephron’
Editorial Board members; should not have been co-
authors or co-workers over the past 3 years nor should they
be persons working in the same institution as yourself or
any of the co-authors.

Conditions
All manuscripts are subject to independent and edito-
rial review. Manuscripts concerning clinical trials will
only be considered if the trial has been fully registered
(see page opposite). Manuscripts are received with the
explicit understanding that they are not under simulta-
neous consideration by any other publication. Submis-
sion of an article for publication implies transfer of the
copyright from the author to the publisher upon accep-
tance. Accepted papers become the permanent property
of ‘Nephron’ journals and may not be reproduced by any
means, in whole or in part, without the written consent
of the publisher. It is the author’s responsibility to obtain
permission to reproduce illustrations, tables, etc. from
other publications.

Conflicts of Interest
Authors are required to disclose any sponsorship or fund-
ging arrangements relating to their research and all
authors should disclose any possible conflicts of interest.
Conflict of interest statements will be published at the
bottom of the title page. Please also supply phone and fax
numbers, as well as e-mail address.

Units: ‘Nephron’ journals require that all articles be sub-
mitted with data in SI units and gravimetric units.

Key words: Please supply 3–10 key words in English that
reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 250 words.
It should be structured as follows:
Background/Aims: What is the major problem that
prompted the study?
Methods: How was the study carried out?
Results: Most important findings?
Conclusion: Most important conclusion?

Footnotes: Avoid footnotes.

Tables and illustrations: Tables are part of the text. Place
them at the end of the text file. Illustration data must be
stored as separate files. Do not integrate figures into the
text. Electronically submitted b/w half-tone and color il-
lustrations must have a final resolution of 300 dpi after
scaling, line drawings one of 800–1,200 dpi.

Color illustrations
Online edition: Color illustrations are reproduced free of
charge. In the print version, the illustrations are repro-
duced in black and white. Please avoid referring to the
colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be
integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic
numerals [in square brackets]. Material submitted for
publication but not yet accepted should be noted as
‘unpublished data’ and not be included in the refer-
ence list. The list of references should include only those
publications which are cited in the text. Number ref-
rences in the order in which they are first mentioned
in the text; do not list alphabetically. The surnames of
the authors followed by initials should be given. There
should be no punctuation other than a comma to sep-
arate the authors. Preferably, please cite all authors.
Abbreviate journal names according to the Index
Medicus system. Also see International Committee of
Medical Journal Editors: Uniform requirements for
manuscripts submitted to biomedical journals (www.
icmje.org).

Examples
(a) Papers published in periodicals: Tomson C: Vascular
calcification in chronic renal failure. Nephron Clin Pract
2003;93:c124–c130.
(b) Papers published only with DOI numbers: Thoerardes TC, Boucher W, Spear K: Serum inter-
leukin-6 reflects disease severity and osteoporosis
in mastocytosis patients. Int Arch Allergy Immunol
DO: 10.1159/000063858.

(c) Monographs: Matthews DE, Farewell VT: Using and
Understanding Medical Statistics, ed 3, revised. Basel,
Karger, 1996.
(d) Edited books: Kashihara N, Sugiyama H, Makino H: Implication of apoptosis in progression of renal diseases;
In: Razzaque MS, Taguchi T (eds): Renal Fibrosis. Con-
Reference Management Software: Use of EndNote is rec-
ommended for easy management and formatting of cita-
tions and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers will assign DOIs as unique identifiers for articles. A DOI number will be printed on the title
page of each article. DOIs can be useful in the future for identifying and citing articles published online without
volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data
that are not necessary for the scientific integrity and conclu-
sions of the paper. Please note that all supplementary
files will undergo editorial review and should be submit-
ted together with the original manuscript. The Editors
reserve the right to limit the scope and length of the sup-
plementary material. Supplementary material must meet
production quality standards for Web publication with-
out the need for any modification or editing. In general,
supplementary files should not exceed 10 MB in size. All
figures and tables should have titles and legends and all
files should be supplied separately and named clearly. Ac-
ceptable files and formats are: Word or PDF files, Excel
spreadsheets (only if the data cannot be converted prop-
erly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach
of your article and gives all users worldwide free and full
access for reading, downloading and printing at www.
Karger.com. The option is available for a one-time fee
of CHF 3000.–, which is a permissible cost in grant al-
location. More information can be found at www.karger.
com/author_choice.

NIH-Funded Research
The US, National Institutes of Health (NIH) mandates
under the NIH Public Access Policy that final, peer-re-
viewed manuscripts appear in its digital database within
12 months of the official publication date. As a service to
authors, Karger submits the final version of your article
on your behalf to PubMed Central. For those selecting
our premium Author’s Choice™ service, we will send
your article immediately upon publishing, accelerating
the accessibility of your work without the usual embargo.
More details on NIH’s Public Access Policy is available

Self-Archiving
Karger permits authors to archive their pre-prints (i.e.
pre-refereeing) or post-prints (i.e. final draft post-refere-
ing) on their personal or institution’s servers, provided
the following conditions are met: Articles may not be
used for commercial purposes, must be linked to the pub-
lisher’s version, and must acknowledge the publisher’s
copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final,
published version of their article, which includes copy-
editing and design improvements as well as citation links.

Page Charges/Length of Paper
There are no page charges for papers of 3 or fewer printed
pages (including tables, figures, references and acknowl-
edgements). Each additional complete or partial page is
charged to the author at CHF 325.–
Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation
Clinical trials provide important information that can profoundly influence the direction of medical research and clinical care. It is crucial that this process is not unduly influenced by selective publication of clinical trial results. Information regarding all clinical trials should therefore be made available to the general public.

In common with other nephrology journals, Nephron requires that from 2006 all submitted manuscripts concerning clinical trials must be registered in a public trials registry.

The full text of a recent statement published by the editors of: Kidney International; The Journal of the American Society of Nephrology; Nephrology, Dialysis, Transplantation; The American Journal of Transplantation; The American Journal of Kidney Diseases, and Transplantation is reproduced below. The policy described in this text has now been formally adopted by Nephron.

‘Medical research can be seriously compromised by the selective publication of clinical trial results. Therefore, it is imperative that information regarding clinical trials should be available to the general public.

We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. Since 1 April 2006, Nephron no longer accepts manuscripts concerning non-registered trials.

‘We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.

We do not advocate any one particular registry, but registration must be with a registry that meets the following minimum criteria:

• Accessible to the public at no charge.
• Searchable by standard, electronic (Internet-based) methods.
• Open to all prospective registrants free of charge or at minimal cost.
• Validates registered information.
• Identifies trials with a unique number.
• Includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include:
• The registry sponsored by the US National Library of Medicine www.clinicaltrials.gov
• The International Standard Randomised Controlled Trial Number registry www.controlled-trials.com
• The Cochrane Renal Group registry www.cochrane-renal.org/trialsubmissionform.php
• The National (UK) Research Register www.update-software.com/national/
• European Clinical Trials Database http://eudract.emea.eu.int/
The presence of endotoxin in the bloodstream is the consequence of an immunological response triggered by bacterial invasion of the host. This condition leads to altered cardiovascular function, lung dysfunction and acute kidney injury. Removing as much as possible of the circulating endotoxin is therefore imperative to mitigate its biological and clinical effects at the cellular, tissue and organ levels. The publication at hand summarizes the basic mechanisms, rationale and clinical results of a new therapeutic approach that promises to attain this goal: it consists of a specific hemoperfusion process that utilizes cartridges with immobilized polymyxin B in an extracorporeal circuit.

Containing contributions by renowned researchers, this book represents a milestone in the field of extracorporeal therapies in sepsis. It will be a valuable reference work for both basic scientists and clinical professionals who want to keep abreast of current developments.
Contents

Minireviews

C194 Orphan Kidney Diseases
Soliman, N.A. (Cairo)

C228 Defining the Role of Renal Transplantation in the Modern Management of Multiple Myeloma and Other Plasma Cell Dyscrasias
Bansal, T.; Garg, A.; Snowden, J.A.; McKane, W. (Sheffield)

Clinical Guidelines

C179 KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (Sheffield)

Original Papers

C185 Cytotoxic CD4+CD28null T Lymphocytes, Systemic Inflammation and Atherosclerotic Risk in Patients with Chronic Kidney Disease
Yadav, A.K.; Lal, A.; Jha, V. (Chandigarh)

C200 Slow Early Graft Function: A Neglected Entity after Renal Transplantation
Nel, D.; Vogel, J.; Muller, E.; Barday, Z.; Kahn, D. (Cape Town)

C205 Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m²
Fafin, C.; Pugliese, P.; Durant, J.; Mondain, V.; Rahelmirinina, V.; De Salvador, E.; Ceppi, C.; Perbost, I.; Rosenthal, E.; Roger, P.M.; Cua, E.; Dellamonica, P.; Esnault, V.; Pradier, C.; Moranne, O. (Nice)

C215 Does Chinese Herb Nephropathy Account for the High Incidence of End-Stage Renal Disease in Taiwan?

Case Report

C223 Pitfalls in the Management of Severe Hyponatraemia
MacEwen, C.; Watkinson, P. (Oxford)
Original Papers

\textbf{e}115 \textbf{Aldosterone Induces Kidney Fibroblast Proliferation via Activation of Growth Factor Receptors and PI3K/MAPK Signalling}  
Huang, L.L.; Nikolic-Paterson, D.J.; Ma, F.Y.; Tesch, G.H. (Clayton, Vic.)

\textbf{e}123 \textbf{Statin Upregulates the Expression of Klotho, an Anti-Aging Gene, in Experimental Cyclosporine Nephropathy}  
Yoon, H.E.; Lim, S.W.; Piao, S.G.; Song, J.-H.; Kim, J.; Yang, C.W. (Seoul)

\textbf{e}134 \textbf{Exocyst Sec10 Is Involved in Basolateral Protein Translation and Translocation in the Endoplasmic Reticulum}  

Minireview

\textbf{p}33 \textbf{Extracellular Pyrophosphate in the Kidney: How Does It Get There and What Does It Do?}  
Moochhala, S.H. (London)

after \textbf{p}38 \textbf{Contents Vol. 120, 2012}
Contents

See the journal website for contents
Dear colleagues,

The biannual Vascular Access Society (VAS) congress is the most important international meeting for vascular surgeons, radiologists, nephrologists, dialysis nurses... – simply for all, who take care of dialysis access patients. The next (8th) VAS congress will be held in Prague on 25–27 April 2013.

Please come to the next VAS congress and hear both traditional and new topics:

- Hands on workshops
- Vascular access ultrasonography
- Vascular maping prior to access creation
- Ultrasound-guided central vein puncture
- Buttonhole technique
- Permanent catheter care

REGISTRATION IS OPEN. Summarize your data and send the abstract or simply come and listen to your colleagues’ experiences.

See you in Prague – probably the most beautiful city in the world!

www.vas2013.org
New anticancer drugs and their effect on the pathologist's role

Changing Pathology with Changing Drugs

Editor
B. Borisch, P. Gaulard

This special issue is devoted to the changing role of pathology in the context of cancer and its treatment with new drugs such as inhibitors of tyrosine kinases, small molecules and antibodies, as well as combination therapies. The analysis of tissues under combined therapy will be a challenge as different changes will intermingle. A further challenge will be the analysis of follow-up biopsies of the same tumor or of secondary tumors following treatment. In future, pathologists are therefore likely to assume a much more active role in the management of cancer, moving from the position of an observer and describer to that of someone who can suggest modalities of personalized therapy based on the functional properties of the cancer cells under scrutiny. New approaches to treat leukemia, lymphoma, skin, breast, kidney and gastrointestinal cancer are discussed in this issue, which is recommended reading to anyone interested in the pathology of cancers under new treatment options.

Contents

Editorial

Changing Pathology with Changing Drugs: Skin Cancer: Karpova, M.B.; Barysch, M.J.; Zipser, M.C.; Schönewolf, N.; French, L.E.; Dummer, R.

Changing Pathology with Changing Drugs: Tumors of the Gastrointestinal Tract: Cervera, P.; Fléjou, J.-F.


The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment: Leong, A.S.-Y.; Zhuang, Z.

Phosphoproteins and the Dawn of Functional Phenotyping: Bodo, J.; Hei, E.D.

Author and Subject Index
Introducing a new concept to treat acute organ damage

Acute Blood Purification

Editors
Hiromichi Suzuki
Hiroyuki Hirasawa

Contents
Preface: Hirasawa, H.; Suzuki, H.
Introduction: Ronco, C.

Current Status

Terminology and Indication
Terminology and Classification of Blood Purification in Critical Care in Japan: Kawanishi, H.
Indications for Blood Purification in Critical Care: Hirasawa, H.

Acute Renal Failure
Septic Acute Renal Failure: Mori, T.; Shimizu, T.; Tanii, T.

Non-Renal Indication


Current Progresses in Methodology in Blood Purification in Critical Care
Current Progress in Blood Purification Methods Used in Critical Care Medicine: Saito, A.
Membrane Materials for Blood Purification in Critical Care: Yamashita, A.C.; Tomisawa, N.
Anticoagulation in Acute Blood Purification for Acute Renal Failure in Critical Care: Shindo, T.

Equipment and Monitoring in Continuous Renal Replacement Therapy: Yamashita, Y.; Tsukamoto, I.; Kanno, Y.; Suzuki, H.
Cytokine Adsorbing Columns: Taniguchi, T.
Plasma Dia-Filtration for Severe Sepsis: Eguchi, Y.
Application of Polymyxin B Convalently Immobilized Fiber in Patients with Septic Shock: Suzuki, H.; Shoji, H.
Special Considerations in Continuous Hemodiafiltration with Critically Ill Pediatric Patients: Shiga, H.; Kikuchi, Y.; Hattori, M.; Hirasawa, H.

Selection of Modality in Continuous Renal Replacement Therapy: Kanno, Y.; Suzuki, H.

New Technology
'Super High-Flux' or 'High Cut-Off' Hemofiltration and Hemodialysis: Naka, T.; Haase, M.; Bellomo, R.

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Please send: ______ copy(ies)
Postage and handling free with prepayment
Payment:
Please charge to my credit card
☐ American Express ☐ Diners ☐ Eurocard
☐ MasterCard ☐ Visa
Card No.:
Exp. date:
CVV/CVC
(3 digits in the signature field on the back of Visa and MasterCard)
☐ Check enclosed ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
Fax: +41 61 306 12 34
E-Mail orders@karger.ch, www.karger.com

Name/Address:
Date:
Signature:
The world of nephrology united in one publication

Nephron journals (Editor-in-Chief: L.G. Fine, Los Angeles, Calif.) consists of three subjournals: Nephron Clinical Practice (Editor: M. El Nahas, Sheffield), Nephron Experimental Nephrology (Editor: J. Hughes, Edinburgh) and Nephron Physiology (Editor: R. Kleta, London).

Each of these three subjournals is under the editorship of an internationally recognised leader and served by a specialised editorial board. This format takes into account the recurring concern of readers that their specific information needs are hardly met by the traditional broad coverage typical of many regular journals. Those with a wide spectrum of interests or institutions can subscribe to the complete Nephron edition (print, online or both), whereas for individuals who are interested in one specialised area only, the online editions of the subjournals are available separately. Apart from high-quality original research, the Nephron journals publish invited minireviews (supplemented with an editorial comment) on up-to-date topics. Clinical physiology, fluid and electrolyte homeostasis and urinary tract function are also addressed, further contributing to a balanced forum for both research and clinical practice.

More information at www.karger.com/nef

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation